Haemonetics (HAE) Misses Q4 EPS by 21c, Revenues Beat; Offers FY22 EPS Guidance Above Consensus

Haemonetics (NYSE: HAE) reported Q4 EPS of $0.46, $0.21 worse than the analyst estimate of $0.67. Revenue for the quarter came in at $225 million versus the consensus estimate of $222.98 million.

Link to 4Q Earnings Release

GUIDANCE:

Haemonetics sees FY2022 EPS of $2.60-$3.00, versus the consensus of $2.56.

For earnings history and earnings-related data on Haemonetics (HAE) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Sinda raises $331M in IPO, reports Q2 net loss of $16.6M
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15